论文部分内容阅读
目的:分析血清CA199、CYFR21-1、CEA、NSE水平检测在肺癌诊断及疗效评估中的临床价值,探讨其与肺癌的相关性。方法:采用化学发光免疫法检测78例肺癌患者、50例肺部良性疾病及50例健康体检者血清CA199、CYFR21-1、CEA、NSE水平,比较治疗前后肺癌患者肿瘤标志物水平的变化。结果:肺癌组血清CA199、CYFR21-1、CEA、NSE水平较对照组、肺良性疾病组均显著升高(P<0.05);Ⅲ-Ⅳ期肺癌患者各肿瘤标志物水平均较Ⅰ-Ⅱ期患者明显升高(P<0.05);四项联合检测的敏感性为79.5%,明显高于CA199、CYFR21-1、CEA、NSE任一单项肿瘤标志物的敏感性(P<0.05);随着疗效的下降,血清CA199、CYFR21-1、CEA、NSE水平逐渐升高(P<0.05)。结论:肺癌患者血清CA199、CYFR21-1、CEA、NSE水平呈高表达状态,且其表达水平与肺癌病情程度密切相关,联合检测有助于提高肺癌诊断的敏感度及指导治疗方案选择。
OBJECTIVE: To analyze the clinical value of serum CA199, CYFR21-1, CEA and NSE levels in the diagnosis and evaluation of lung cancer, and to explore its correlation with lung cancer. Methods: The levels of serum CA199, CYFR21-1, CEA and NSE in 78 patients with lung cancer, 50 patients with benign lung disease and 50 healthy controls were detected by chemiluminescence immunoassay. The changes of tumor markers in patients with lung cancer before and after treatment were compared. Results: The levels of serum CA199, CYFR21-1, CEA and NSE in lung cancer group were significantly higher than those in control group and benign lung disease group (P <0.05). The levels of tumor markers in stage Ⅲ-Ⅳ lung cancer patients were significantly higher than those in stage Ⅰ-Ⅱ (P <0.05). The sensitivity of the four combined tests was 79.5%, which was significantly higher than that of any single tumor marker of CA199, CYFR21-1, CEA and NSE (P <0.05) The curative effect decreased, serum CA199, CYFR21-1, CEA, NSE levels gradually increased (P <0.05). Conclusions: Serum levels of CA199, CYFR21-1, CEA and NSE in patients with lung cancer are highly expressed, and their expression levels are closely related to the degree of lung cancer. Combined detection may help to improve the sensitivity of lung cancer diagnosis and guide the selection of treatment options.